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The frequency of infection with the six classified major genotypes of hepatitis C virus (HCV) was investigated
in 447 infected volunteer blood donors from the following nine countries: Scotland, Finland, The Netherlands,
Hungary, Australia, Egypt, Japan, Hong Kong, and Taiwan. Viral sequences in plasma from blood donors
infected with HCV were amplified in the 5'-noncoding region and were typed by restriction fragment length
polymorphism analysis. Electrophoresis of DNA fragments produced by cleavage with HaeIII-RsaI and
ScrFI-Hinfl allowed HCV types 1 (or 5), 2, 3, 4, and 6 to be identified. Further analysis with MvaI-Hinfl allowed
sequences of the type 5 genotype to be distinguished from sequences of the type 1 genotype. Types 1, 2, and 3
accounted for almost all infections in donors from Scotland, Finland, The Netherlands, and Australia. Types
2 and 3 were not found in the eastern European country (Hungary), where all but one of the donors were
infected with type 1. Donors from Japan and Taiwan were infected only with type 1 or 2, while types 1, 2, and
6 were found in those from Hong Kong. HCV infection among Egyptians was almost always by type 4. Donors
infected with HCV type 1 showed broad serological reactivity with all four antigens of the second generation
Chiron RIBA-2 assay (Chiron Corporation, Emeryville, Calif.), while infection with divergent HCV genotypes
elicited antibodies mainly reactive to c22-3 and c33c. Reactivities with antibodies 5-1-1 and clOO-3 were
infrequent and were generally weak, irrespective of the geographical origin of the donor. Because the envelope
region of HCV is even more variable than the NS-4 region, it is likely that vaccines based on these proteins need
to be multivalent and perhaps specifically adapted for different geographical regions.
The discovery of hepatitis C virus (HCV) (6) and the
development of serological screening assays for HCV antibody
in blood donors has provided a valuable method for the
prevention of posttransfusion non-A, non-B hepatitis. The orig-
inal anti-HCV enzyme immunoassay (EIA) used a recombi-
nant protein, clOO-3, derived from the NS-4 region of the viral
genome as the solid-phase antigen in an indirect enzyme-
linked immunosorbent assay (ELISA) and proved to be capa-
ble of detecting most, but not all, blood donations implicated
in the transmission of HCV to recipients (12, 14). Second-
generation ELAs include recombinant antigens from the core
and NS-3 regions of HCV and are capable of detecting HCV
antibody in blood donors and hemophiliacs at much higher
rates (1). However, some HCV-infected blood donors may not
be detected because of the delay between primary infection
and seroconversion to positivitv for antibody to HCV. Alter-
natively, infection with HCV isolates with sequences divergent
from those of the prototype virus may elicit antibodies that do
* Corresponding author. Mailing address: Department of Medical
Microbiology, Medical School, Teviot Place, Edinburgh EH8 9AG,
United Kingdom. Phone: +44 31 650 3138. Fax: +44 31 650 6531.
not cross-react with the antigens used in current screening
assays.
Comparison of the complete genomic sequences of HCV
reveals considerable heterogeneity between different isolates.
For example, the prototype virus (HCV-1) (8) and HCV type
HC-J6 (22) show a 33% nucleotide sequence divergence that
is distributed throughout the genome in regions encoding both
structural and nonstructural proteins (21). Divergence is most
extreme for the envelope proteins and the part of the NS-4
gene that codes for the clOO-3 antigen, with only 50%
predicted amino acid sequence identity between different
HCV genotypes.
HCV has been classified into a number of distinct groups or
genotypes on the basis of the sequence similarities of com-
plete genomic sequences (21) or fragments amplified by PCR
(3, 4, 11, 19). Unfortunately, there are at least three different
classification systems in the literature, and this has caused
confusion and difficulty when results from different research
groups are compared. However, several laboratories studying
viral sequence variation have agreed upon a standardized
system of HCV nomenclature (25) that reflects the two-titered
nature of sequence variability. All known variants can be
classified into a total of six major genotypes (types 1 to 6), of
884
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which four (types 1 to 4) contain several more closely related
subtypes (e.g., a, b, and c).
Variants previously described as belonging to types or
groups I and 11 (3, 13, 19, 21) are designated types la and lb.
The more divergent HCV types, such as HC-J6 and HC-J8 (21,
22), are designated types 2a and 2b, respectively. Variants
described as type 3 (4), type IV (3), or types V and VI (19) are
grouped together as type 3, with two subtypes (subtypes a and
b). HCV variants detected in the Middle East and Africa
initially described as "type 4" (26) retain their designation as
type 4a, as do the group V variants found in South Africa (type
5a) (2, 3). Finally, some blood donors and patients with non-A,
non-B hepatitis from Hong Kong are infected with a variant of
HCV characterized by a 2-base insertion in the 5'-noncoding
region (5'-NCR) (2, 26); sequence analysis of NS-5 indicated
that it represents another major genotype of HCV, now
designated type 6a (25).
The six major genotypes have distinct nucleotide sequences
in the 5'-NCR (2, 26), and so viruses can be typed by restriction
fragment length polymorphism (RFLP) analysis of DNA am-
plified from that region of the viral genome by reverse
transcription and then PCR (18, 20). However, there are few,
if any, consistent differences in the 5'-NCR sequences of
subtypes within a single genotype (e.g., between types la and
lb), and so it is not generally possible to differentiate them
reliably by the type of RFLP assay described here. In the study
described here, we explored the distributions of the major
genotypes without attempting to identify specific subtypes in
particular countries.
The development of typing assays based on RFLP requires
considerable amounts of comparative sequence data, because
there is also some intratypic sequence variability that may lead
each genotype to show more than one electropherotype (18,
20). Furthermore, existing assays may need to be modified as
more HCV genotypes are discovered. For example, by using
HaeIII-RsaI and ScrFI, it was possible to identify HCV types 1,
2, and 3 (18), but we have since found that HCV variants of
type 4 (26) show the same electropherotype as type 1 with
these restriction enzymes. We therefore modified the assay by
using Hinfl in combination with ScrFI to differentiate the two
genotypes. Type 6 can also be identified by using these
restriction enzymes by virtue of insertions in the 5'-NCR that
lead to detectable size variations in one of the cleaved frag-
ments of DNA. Finally, we analyzed sequences showing type 1
electropherotypes with a new combination of restriction endo-
nucleases (MvaI-Hinfl) to differentiate type 1 variants from
type 5 variants.
In the current study, we investigated the distributions of the
six recognized genotypes in 447 anti-HCV-positive volunteer
blood donors from the following nine different countries:
Scotland, Finland, The Netherlands, Australia, Egypt, Hun-
gary, Japan, Hong Kong, and Taiwan. Serological reactivities
to a series of structural and nonstructural HCV type 1 antigens
in the Chiron recombinant immunoblot assay (RIBA-2) of
samples from donors infected with different genotypes were
assessed in parallel.
MATERIALS AND METHODS
Plasma samples. Samples from volunteer blood donors from
Scotland, Egypt (expatriates working in Riyadh, Saudi Arabia),
Finland, The Netherlands, Hungary, Australia, and Hong
Kong were available from routine second-generation anti-
HCV ELISA screening (Ortho Diagnostics Systems, Raritan,
N.J., or Abbott (GmBH, Wiesbaden-Delkenheim, Germany).
Samples from Japan were screened by anti-HCV passive
hemagglutination assay by using erythrocytes coated with
PHCV-34 and PHCV-31 antigens (Dainabot Co. Ltd., Abbott,
Japan). Samples from Taiwan were screened by using a
second-generation ELISA with HCV antigens equivalent to
c22-3, c33c, and c100-3.
Donations from Finland, The Netherlands, Hungary, Aus-
tralia, and Egypt that were repeatedly reactive on screening by
the Abbott or the Ortho second-generation assays were tested
further by the RIBA-2 assay (Chiron Corporation, Emeryville,
Calif.) (see Table 1). Samples that were confirmed to be
positive (significant reactivity with two or more recombinant
antigens) or indeterminate (reactivity with one antigen) were
shipped frozen to Edinburgh for further analysis by PCR. In
Hong Kong, the Abbott Matrix assay was used for supplemen-
tary testing. Samples from Japanese donors that were reactive
on screening and that showed titers of >212 in the HCV
passive hemagglutination assay were referred to Edinburgh,
while those from Taiwanese donors were referred without
prior confirmatory testing. In interpreting the RIBA-2 assay
results, we considered that reactivities with the 5-1-1 and
c100-3 antigens do not represent true confirmation of positive
results, since both antigens are derived from the same region of
NS-4 and could be reacting with the same epitope in both
proteins. In the present study, samples showing this type of
dual reactivity were considered indeterminate (see Table 4).
HCV typing. RNA PCR was carried out as described previ-
ously (4) by using primers matching conserved regions in the
5'-NCR. The PCR assay has proved to be both sensitive and
specific for the detection of HCV RNA sequences in plasma
(9). To monitor possible contamination with exogenous se-
quences during extraction or setting up of the amplification
reactions, RNAs from at least three negative control plasma
samples were extracted, reverse transcribed, and amplified in
each batch of donor samples examined by PCR. On no
occasion were false-positive results obtained with these nega-
tive controls. The PCR product was radiolabelled by the
addition of [35S]dATP in the second PCR stage. Two aliquots
of product DNA were cleaved with HaeIII-RsaI, ScrFI-Hinfl,
or MvaI-Hinfl as described previously (18), and the DNA
fragments were electrophoresed on a high-resolution (nonde-
naturing) polyacrylamide gel that allowed fragments of 30 to
500 bp to be resolved.
The nomenclature for the bands produced by HaeIII-RsaI
and ScrFI-Hinfl broadly follows that described previously (18),
but with additional patterns for genotypes 4 and 6. For
simplicity, the two patterns with ScrFI (ScrFI-Hinfl) which
were not distinguishable (patterns A and B) by electrophoresis
are referred to here as pattern A. Similarly, a rare C-*T
change found in type 3 and type 4 sequences at position -220
(e.g., E-bl [4] and EG-33 [26]) creates a new Hinfl site, but the
position of cleavage is 3 bp downstream from a conserved
ScrFI or MvaI site. Because these two sites could not be
cleaved simultaneously, the polymorphism would not affect the
overall band patterns. Since there are no other variable Hinfl
or ScrFI sites in type 3 and 4 sequences, we assigned a single
letter (G and H, respectively) to each sequence.
Nucleotide sequencing. To investigate samples showing un-
usual electropherotypes (n = 2) or to confirm the identities of
samples showing unexpected distributions (n = 3), the 5'-NCR
was amplified with unlabelled nucleotide triphosphates and
directly sequenced by using both sense and antisense inner
primers as described previously (4).
New sequences described in this report have been submitted
to GenBank (accession numbers L28057 and L28058).
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FIG. 1. Predicted association of different cleavage patterns of the 5'-NCR with sequences of HCV types 1 to 6 by cleavage with HaeIII-RsaI
(A), ScrFI-Hinfl (B), and MvaI-Hinfl (C). The sources of type 1 (n = 69), 2 (n = 21), and 3 (n = 30) sequences were given previously (18), and
some were published elsewhere (2, 28); the sequences of type 4 (n = 18) (26), type 5 (n = 4) (2), and type 6 (n = 5) (2, 26) have been described
previously. The locations of cleavage sites are indicated by vertical lines in the box on the left; the positions of 1- or 2-bp insertions found in some
5'-NCR sequences are represented by #; the expected sizes of fragments are given in base pairs. The numbers of published sequences of each
genotype associated with each pattern are given in the box on the right.
RESULTS
HCV typing method. The predicted cleavage patterns of
sequences corresponding to the region in the 5'-NCR ampli-
fied by PCR varied considerably among the different major
types of HCV (Fig. 1). By using the combination HaeIII-RsaI,
patterns designated a and b were predicted for published type
1, type 4, and type 5 sequences, while patterns designated c, d,
and e were uniquely associated with type 2 (Fig. 1A). Patterns
f and g should be produced by all known type 3 sequences, and
pattern h should be produced by all known type 6 sequences.
The latter pattern differed from pattern d (type 2) by the two
insertions (a total of 3 bp) in the 114-bp fragment. This size
difference can readily be resolved by polyacrylamide gel elec-
trophoresis of the cleaved DNA.
The second set of restriction enzymes (ScrFI-Hinfl) pro-
duced different bands for five of the six HCV genotypes (Fig.
IB). For type 6 sequences, a 3-bp insertion in the 35-bp
fragment (pattern I) distinguished them from type 1 sequences
(pattern A; 32 bp). With neither combination of enzymes was
it possible to distinguish type 5 from type I sequences.
However, these two genotypes can be reliably differentiated by
using MvaI-Hinfl (Fig. IC), in which of a total of four possible
electropherotypes, all type 1 sequences produce pattern A and
all type 5 sequences produce pattern D. These enzymes also
distinguish many of the other genotypes, and in principle, it
would be possible to identify all six by cleavage with HaeIII-
RsaI in one reaction and by cleavage with MvaI-Hinfl in the
other.
Identification of HCV genotypes in blood donors. Viral
RNA sequences could be amplified from a total of 421 of the
526 RIBA-2 assay-positive samples from volunteer blood
donors (80%) and from 26 of the 430 RIBA-2 assay-indeter-
minate samples (6%) (Table 1). The incidence of confirmed
HCV infection (samples that were either RIBA-2 assay posi-
tive or PCR positive) varied from 0.01% (Finland, The Neth-
erlands) to more than 8% (Egypt).
Amplified sequences from each of the 447 PCR-positive
samples were typed by RFLP analysis by using the restriction
endonucleases HaeIII-RsaI and ScrFI-Hinfl (Table 2). A wide
range of electrophoretic patterns was found in the study
samples, but almost all could be assigned to those predicted for
published sequences (n = 443; Table 2). In no case were there
incompatible combinations of RFLP patterns between the two
sets of enzymes (Fig. 2A), and sequences from all 443 samples
could be assigned to types 1 (type 5), 2, 3, 4, and 6. Because
sequences of genotype 5 produce the same RFLP patterns as
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TABLE 1. Supplementary testing of blood repeatedly reactive upon screening by second-generation EIAs
No. of No. of RIBA-2 assay-positive (no. No. (%)
Country donors Supplemcntary No. of of PCR-positive) samples of PCR- % Infected
screened' test samplesh positive donors"Confirmed' Indeterminedf samples'
Scotland 302,231 RIBA-2 510 203 (129) 307 (15) 144 (28) 0.07
Australia 20,000 Abbott (2 48 27 (22) 21 (2) 24 (50) 0.15
beady
Finland 137,000 RIBA-2 75 15 (10) 60 (2) 12 (16) 0.01
The Netherlands 321,400 RIBA-2 34 30 (27) 4 (4) 31 (91) 0.01
Hungary 9,707 RIBA-2 73 48 (44) 25 (3) 47 (64) 0.53
Egypt 264 RIBA-2 33 23 (19) 10 (0) 19 (58) 8.7
Taiwan 5,914 NDh 100 99 (93) 1 (0) 93 (93) 1.7
Japan 4,400 ND 44 44 (40) 0 (0) 40 (91) 1.0
Hong Kong 29,000 Abbott (Matrix) 39 37 (37) 2 (0) 37 (95) 0.13
Total 956 526 (421) 430 (26) 447 (47)
a Donor samples from Scotland and Finland were part of a consecutive series; for The Netherlands, Hong Kong, and Australia, an estimate of the number of
donations from which the samples were derived was made.h Number of EIA-positive samples reactive with one or more antigens in the RIBA-2 assay.
Samples either positive or indeterminate by the RIBA-2 assay were further tested by PCR; the HCV type was determined for all PCR-positive samples.
"Approximate incidence of infection obtained by dividing the number of confirmed infected donors (RIBA-2 assay positive or RIBA-2 assay indeterminate, PCR
positive) by number of donations screened.
e Confirmed by the RIBA-2 assay (significant reactivity to two or more HCV recombinant antigens).
f Indeterminate by the RIBA-2 assay (reactivity to a single HCV antigen).
g Abbott (2 bead), two-bead supplementary assay (Abbott).
" ND, not done.
those of type 1 with both sets of restriction endonucleases (Fig.
IA and B), a third cleavage reaction with Mval-Hinfl was
carried out on the 252 samples showing the aA or bA
electropherotypes (Fig. 2B). All but one sample showed the A
electropherotype indicating type 1, while the exception showed
the D pattern, which is consistent with a type 5 sequence.
Types 1, 2, and 3 were found among samples from the three
western European countries surveyed and Australia, with types
1 and 3 being similar in prevalence and type 2 forming
approximately 20% of the total (Table 3). One Dutch donor
was infected with a variant that showed an RFLP pattern with
ScrFI-Hinfl that is usually associated with type 4; the DNA in
that sample was sequenced and found to be similar to those
obtained from the Middle East and Egypt (26), Zaire (2), and
Burundi (28) and which were previously assigned to the type 4
genotype (26, 28). Upon checking of the donor's records, this
individual was found to have originated from Indonesia and
may have acquired the HCV infection there. The one sample
identified by RFLP as type 5 (bA, D with MvaI-Hinfl) origi-
nated from Australia; direct nucleotide sequence analysis
confirmed its identity as type 5, because it was identical to the
5'-NCR sequences of the previously identified type 5 variants
SAI, SA3, SA7, and SAl1 (2, 25). This donor was of French
and Polish ancestry. Her only admitted risk factor for HCV
infection was a blood transfusion that she received in France.
No history of travel to South Africa was reported. The
distribution of HCV genotypes was markedly different in
Hungary, where all but one of the donors were infected with
type 1. The one exception produced an RFLP pattern consis-
tent with type 4 (aH), an identification also confirmed by direct
sequence analysis.
Type 1 was also the most frequently found genotype in
countries in the Far East, although samples from those coun-
tries differed from many of those from Europe by the complete
absence of HCV type 3. Approximately a quarter of donors
from Hong Kong were infected with a novel HCV type,
designated type 6 (2, 25, 26). A completely different distribu-
tion of HCV infection was found in Egypt, where all donors
whose HCV strains could be typed (17 of 19) were infected
with HCV type 4 (25, 26).
Only two of the donors showed evidence of infection with
more than one genotype. Both of these were from Hong Kong
TABLE 2. Distributions of electropherotypes among donors from different countries
No. of donor samples of electropherotype":
Country
aA bA cD dD eD dE eE fG gG aH bH hI
Scotland 4 63 10 2 3 4 2 48 8
Australia 1 12 1 1 1 8
Finland 3 5 4
The Netherlands 18 2 3 2 5 1
Hungary 45
Egypt 12 5
Japan 31 6 2 1
Taiwan 1 52 16 5 7 6 6
Hong Kong 1 21 1 12
' The first letter (lowercase a to h) indicates the cleavage pattern observed upon digestion with HaeIIl-RsaI (Fig. IA). The second letter (capital A to 1) refers to
the cleavage pattern observed upon digestion with ScrFI-Hi,zfl (Fig. IB).
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c 35 --
d - - 12 20 - - - - 2
e __ 11 8 6- -
f - -65_ 3
h - - - - - - - 12 6




a 8 - - - 1,b 244 - - 1 4,5~
d - - - 2
e - - -
f - - - 3
g - - -
Ih - 6
1 6 2, 53,4
FIG. 2. Observed combinations of cleavage patterns with HaeIII-RsaI (a to h; left margin), ScrFI-Hinfl (A to I; top margin), and MvaI-Hinfl
(A to D; top margin) for identification of genotypes 1 to 6 in blood from 443 donors. The specific genotypes associated with cleavage patterns are
shown on the right and lower margins (see Fig. 1). For MvaI-Hinfl, only those samples showing RFLP pattern a or b with HaeIII-RsaI were tested
further with MvaI-Hinfl.
and showed a mixed pattern of type 1 and type 6 electrophero-
types. Coinfection with two genotypes was confirmed by limit-
ing dilution of cDNA amplification of single molecules by
nested PCR (24). RFLP analysis of DNAs amplified from five
single molecules yielded three type 1 and two type 6 sequences
from one of the two donors who showed this type of mixed
pattern.
Two of the 19 samples from Egypt produced anomalous
RFLP patterns, producing bands with HaeIII-RsaI larger than
any of those predicted in Fig. 1A. Sequence analysis confirmed
that an A->U or an A--C change at position - 176 eliminated
the usually well conserved RsaI site to produce bands of 44, 173
(i.e., 58 plus 115 bp [see pattern a]), 9, and 26 bp or 217 (i.e.,
102 plus 115 bp [see pattern b]), 9, and 26 bp. The first
sequence showed the greatest similarity to those of type 4; they
were both left unassigned until we obtain sequence data for the
NS-5 region to allow formal classification (25) (see Discus-
sion).
Serological reactivity. Irrespective of the geographical ori-
gins of the donors, sera from those infected with HCV type 1
showed broad reactivities with all four antigens in the second-
generation RIBA-2 assay, with a high mean score in all cases
(Fig. 3; Table 4). The antibody response elicited by infection
with HCV types 2, 3, 4, and 6 showed reactivity that was largely
restricted to c33c and c22-3 antigens (Fig. 3). Reactivity to the
5-1-1 antigen was found in 79, 17, 7, 42, and 33% of donors
infected with types 1, 2, 3, 4, and 6, respectively, and reactivity
to the clOO-3 antigen was found in 78, 34, 33, 58, and 58%,
respectively (Table 4). There was a significant difference
between the proportion of type 1 samples that were reactive
with antigen 5-1-1 compared with the proportion of samples of
the other four genotypes that were reactive with antigen 5-1-1,
either individually (type 2, P < 0.0001; type 3, P < 0.0001; type
4, P < 0.001; type 6, P < 0.001) or collectively (X2 = 176; 4
degrees of freedom on a 2-by-2 contingency table; P < 0.0001).
There were also significant differences between type 1 and
types 2, 3, 4, and 6 in the frequency of reactivity to antigen
clOO-3 (P < 0.0001, P < 0.0001, P < 0.05, and P 0.1 for types
2, 3, 4, and 6, respectively). Between type 1 and the four
genotypes together, there was a highly significant difference (X2
= 82; 4 degrees of freedom; P < 0.0001).
Only 26 of 430 (6%) RIBA-2 assay-indeterminate samples
were PCR positive, whereas 421 of 526 (80%) samples con-
firmed to be positive by the RIBA-2 assay were PCR positive
TABLE 3. Prevalence of HCV types in different donor populations
No. of No. (%) of donor samples of HCV genotype:
samplesa 1 2 3 4 5 6
Scotland 144 67 (47) 21 (14) 56 (39) 0 0 0
Australia 24 12 (50) 3 (13) 8 (33) 0 1 (4) 0
Finland 12 3 (25) 5 (42) 4 (33) 0 0 0
The Netherlands 31 18 (58) 7 (23) 5 (16) 1 (3) 0 0
Hungary 47 46 (98) 0 0 1 (2) 0 0
Egypt lgb 0 0 0 17 (90) 0 0
Taiwan 93 53 (57) 40 (43) 0 0 0 0
Japan 40 31 (77) 9 (23) 0 0 0 0
Hong Kong 37c 22 (59) 1 (3) 0 0 0 12 (32)
Total 447 252 86 73 19 1 12
a Number of PCR-positive samples typed by RFLP.b Two donors were infected with variants that could not be classified as type 1 to 6.
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FIG. 3. Frequency of reactivities to antigens in the RIBA-2 assay by samples from blood donors infected with different genotypes of HCV. The
values above the histogram indicate the mean score for each type with each antigen, from 0 (nonreactive) to 4+. Samples from 252 type 1-, 86 type
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TABLE 4. Patterns of serological reactivity in Chiron RIBA-2 assay associated with different genotypes of HCV
RIBA-2 pattern No. of No. No. of donor samples of HCV genotype:
Sample samples PCR5-1-1 c100-3 c33c c22-3 positive 1 2 3 4 5 6 U" Mb
Confirmed by RIBA-2
assay + + + + 271 222 187 15 5 8 0 4 1 2
+ - + + 19 12 12 0 0 0 0 0 0 0
- + + + 70 50 10 14 19 3 1 3 0 0
- - + + 166 137 33 56 35 7 0 5 1 0
Subtotal 526 421 242 85 59 18 1 12 2 2
Indeterminate by
RIBA-2 assay + - - - 8 0 0 0 0 0 0 0 0 0
- + - - 51 0 0 0 0 0 0 0 0 0
- - + - 24 2 2 0 0 0 0 0 0 0
- - - + 339 24 8 1 14 1 0 0 0 0
+ - - 8 0 0 0 0 0 0 0 0 0
Subtotal 430 26 10 1 14 1 0 0 0 0
"U, two samples from Egyptian donors could not be classified by RFLP analysis (see text).
b M, two samples showed evidence of mixed infection with types 1 and 6.
Samples showing reactivities to proteins 5-1-1 and clt)t)-3 were not considered confirmed for the reasons described in the text.
(Table 4). All samples that were indeterminate and that were
reactive with the NS-4-derived proteins clOO-3 or 5-1-1 were
PCR negative, while a significant proportion of those showing
an indeterminate reaction with the c33c or c22-3 antigen were
PCR positive (2 of 24 and 23 of 339 samples, respectively).
Approximately 20% of samples from donors infected with type
3 were reactive with c22-3 only, whereas 3% of samples from
those infected with type 1 were reactive with c22-3 only (X2 =
23; P < 0.0001). However, sequence variability was not the
only cause of restricted serological reactivity, because many of
the samples that failed to react with antigens clOO-3 and 5-1-1
were obtained from donors infected with type 1 (10 of 430
RIBA-2 assay-indeterminate samples and 33 of the 166 sam-
ples that were reactive with antigens c22-3 and c33c only). We
are analyzing whether this restricted pattern of reactivity is
associated with proximity to seroconversion by testing previous
donations and follow-up samples from the donors. From
retrospective testing, we found that the type 1-infected donor
whose sera reacted with antigen c33c only (Table 4) showed a
similar serological profile for at least 2 years (data not shown).
DISCUSSION
In the study described here, we modified an existing typing
assay so that all six known major genotypes of HCV could be
recognized. By the addition of Hinfl to ScrFI, a novel site
present in all type 4 (and type 3) variants resulting from a
change from U to C at position - 166 could be recognized.
New cleavage patterns resulting from the 3-base insertion in
the 5'-NCR of type 6 variants were also classified in the study
as electropherotype h with HaeIII-RsaI and electropherotype I
with ScrFI-Hinfl. The type 5 sequences could be distinguished
from type 1, replacing ScrFI (GGnCC) with MvaI (GG[A/
T]CC) to identify the A/G polymorphism at position - 162 and
the U/C polymorphism at position - 121. We are in the
process of exploring whether MvaI-Hinfl can be used to
entirely replace the original ScrFI-Hinfl combination for the
identification of all six genotypes, as suggested by analysis of
the predicted fragment patterns of the published sequences
(Fig. IA and C).
The main problem with any HCV typing assay is the need for
continual modifications as new HCV genotypes are discovered.
Many of the assays that use type-specific primers could be
predicted to either fail to differentiate genotypes or fail to
amplify sequences unrecognized when the primers were orig-
inally designed. For example, none of the primers used for the
identification of genotypes I, II, III, and IV (types la, lb, 2a,
and 2b, respectively) described by Okamoto et al. (23) would
be likely to amplify either type 3 or type 4 sequences. Similarly,
type-specific probes for amplified NS-5 or 5'-NCR based on
these genotypes would fail to hybridize or would hybridize
inappropriately to many of the newly recognized genotypes
(11, 28, 31).
There is now a considerable amount of comparative se-
quence data on the 5'-NCRs of HCV types 1, 2, and 3 from
several geographical regions. It is therefore possible to predict
a comprehensive range of possible electropherotypes with the
restriction enzymes used in the present study and to reliably
differentiate these genotypes from each other. However, the
designation of specific electropherotypes to HCV types 4, 5,
and 6 is preliminary at this stage because so few sequences in
the 5'-NCR have been described. For example, the existence of
types 4, 5, and 6 is based on phylogenetic analysis of 3, 4, and
1 sequences, respectively, in the NS-5 region (25). Each of
these new genotypes contains sequences that are distinct in the
5'-NCR, and to date, a total of 18, 6, and 6 5'-NCR sequences
similar to those of types 4, 5, and 6 that have been definitively
genotyped have been published (2, 26). It is likely that a wider
range of electropherotypes will be found for these genotypes,
and continuous modification of Fig. 1 will be required as new
data accumulate. Indeed, some of the sequences closely resem-
bling type 4 (26), but which were obtained from West Africa
rather than the Middle East (2, 28), would produce patterns
with HaeIII-RsaI other than a and b, although all would
produce the C electropherotype with MvaI-Hinfl.
Finally, the method described here detects only the majority
circulating sequence of HCV; coinfection with two or more
genotypes is apparent only when approximately equimolar
concentrations of different sequences are present within a
sample. Our finding of only two coinfections (both from Hong
Kong donors infected with type 1 and type 6) could clearly be
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an underestimate of the true rate of mixed infections. Assays
based on type-specific amplification of different genotypes
would be expected to be more sensitive indicators of multiple
infections (16, 23), provided that separate amplification reac-
tions were carried out for each pair of type-specific primers.
Accepting the above qualifications, it is clear from this first
large-scale survey of blood donors that major differences in the
geographical distributions of HCV variants exist. Donors in
western European countries (Scotland, Holland, and Finland)
were almost exclusively infected with types 1, 2, and 3, while
those in the Far East (Japan, Taiwan, and Hong Kong) were
mainly infected with type 1, with lower frequencies of infection
with type 2 (and type 6 in Hong Kong). The situation is highly
complex and difficult to interpret because there are genotypes
with worldwide distributions (e.g., types 1 and 2) that coexist
with those which are apparently confined to specific geograph-
ical areas (types 4 and 6).
The data from blood donors presented here are consistent
with those obtained from smaller surveys of a variety of
different patient groups with non-A, non-B hepatitis or hepa-
tocellular carcinoma (16, 29-31). However, these latter studies
are potentially biased toward those genotypes that are more
likely to cause more severe liver disease. Current evidence
suggests that genotype 1 is associated with a higher rate of
chronic active hepatitis or cirrhosis than is genotype 2, 3, or 4
(10) and is associated with a much poorer response to treat-
ment with alpha interferon than are type 2 (15, 29, 33) and type
3 (10). It is perhaps significant that among the asymptomatic
blood donors in the present study, we found a much higher rate
of non-type 1 variants (43%) than in previous surveys (20, 23,
30, 31).
Any attempt to interpret these geographical differences is
hampered by current ignorance surrounding the method of
virus transmission. Needle sharing, transfusion of blood and
blood products, tattooing, and other forms of parenteral
exposure have been implicated in the transmission of HCV,
while current evidence suggests that the intrafamilial, mother-
to-child, sexual, and intrafamilial forms of transmission are
relatively inefficient modes of virus spread. There is therefore
little understanding of how or whether HCV might spread in
societies where blood transfusion and parenteral drug abuse
are uncommon. As an example of the difficulty in interpreting
the current data, the similarities in the distributions of HCV
genotypes in Australia and western Europe (and their differ-
ence from the genotypes in other Far East countries) could be
explained by assuming an ancient origin for HCV and relating
the distributions of genotypes of the majority of Australian
blood donors to their original European ancestry. On the other
hand, it might be that HCV was introduced relatively recently
by needle sharing among HCV-infected drug abusers from
Europe or the United States.
The existence of variants of HCV that show up to 30%
sequence diversity could potentially lead to significant anti-
genic variations among homologous proteins encoded by the
different genotypes of HCV. The effects that this sequence
variation would have on the effectiveness of antibody screening
for HCV remains a relatively unexplored area. All currently
used assays use antigens derived from HCV type 1 sequences
and rely on cross-reacting antibodies to detect infection with
other HCV genotypes. This is illustrated by the first-generation
assays that used the clOO-3 recombinant protein derived from
NS-4. The antigenic region was found to be particularly
variable in sequence between HCV types 1, 2, and 3 (27) and
led to a low rate of detection of infection with variants other
than type 1 (5, 18). In the present study, we showed that the
majority of individuals infected with genotypes 2 to 6 showed
weak or absent reactivity to c100-3, confirming our previous
observations for types 2 and 3 on a relatively smaller number of
individuals (18). This lack of cross-reactivity provides at least
one explanation for the continuing transmission of HCV by
blood screened by anti-CIOO assays alone (12, 14).
All donors infected with HCV types 2 to 6 reacted with the
recombinant core protein c22-3, probably reflecting the pro-
tein's greater degree of amino acid sequence conservation
(90%) than that among the nonstructural proteins (75 to 80%).
However, this observation is misleading, because c22-3 is a
component of screening and confirmatory assays for HCV
infection. In interpreting these results, the preselection by the
screening assays precluded an analysis of the proportion of
donors with infections with divergent HCV types that elicited
an even more restricted serological response so as to be
undetectable by current blood donor screening assays. The
actual frequency with which samples from individuals infected
with variants other than type 1 are missed by current second-
generation screening assays (which contain c33c and c22-3 as
well as NS-4 proteins) is unknown, but it is probably low.
However, it is recognized that the serological response to
HCV-encoded antigens is often narrow in specificity and is
generally of low titer. Acute infections with HCV following
transfusion of infectious blood or blood products may fail to
elicit antibodies for several months (32). Furthermore, individ-
uals who are only marginally immunosuppressed (such as
patients undergoing renal dialysis, elderly people, hemophili-
acs, and neonates) generally show extremely restricted and
idiosyncratic patterns of serological reactivity, often to only
one (or possibly none) of the four antigens used in current
screening assays (17). In all of these cases, it is clearly desirable
to have a test that is optimally sensitive for all variants of HCV.
Evaluation of assays that incorporate additional peptide anti-
gens corresponding to epitopes of other HCV types not shared
with type 1 may represent a first step in improving current
assays.
A recent report described the immunization of several
chimpanzees with El and E2 proteins produced in mammalian
cells and their protection from infection with homologous type
virus (type 1) (7). However, these viral envelope glycoproteins
have highly variable sequences among different genotypes of
HCV. For example, amino acid sequence similarities of 55 and
74% were found upon comparison of the El and E2 proteins,
respectively, of a type 1 and a type 2 variant (HCV- 1 and
HC-J8) (21). By analogy with other enveloped viruses, it is
likely that the antibodies elicited by one genotype will not
protect an individual from reinfection with heterologous vari-
ants. Indirect evidence for this possibility is shown by the
frequent detection of infection with multiple genotypes in a
variety of different patient groups (23, 27). These data suggest
that a fully protective vaccine may have to contain a range of
different envelope proteins corresponding to the common
genotypes in particular geographical regions. For example,
those for use in western Europe might include the El and E2
proteins from HCV types 1, 2, and 3, while those for use in the
Middle East might be based on type 4 sequences.
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